Suzhou Motif Biotech Co., Ltd. is an innovative biotechnology company dedicated to the research, development, and production of peptide Active Pharmaceutical Ingredients (APIs) and related products. Located in the Suzhou High-Tech Zone (Huqiu District), the company was founded in 2021 and commenced its research and manufacturing operations in March 2023.

Driven by core peptide technologies, Motif Biotech has established an integrated CRDMO (Contract Research, Development, and Manufacturing Organization) platform. This platform seamlessly combines peptide discovery, process development, and API manufacturing to provide end-to-end solutions for global partners.

The company has invested over 100 million RMB in R&D infrastructure, operating more than 100 R&D laboratories within a 4,300-square-meter facility. It currently possesses an annual peptide (API) production capacity exceeding 30 kilograms. Furthermore, Motif Biotech has built an 800-square-meter GMP manufacturing facility that operates in strict compliance with ICH Q7 guidelines. Its production and quality management systems are designed to meet the regulatory requirements of the FDA (U.S.), EMA (EU), and NMPA (China).

With a team possessing decades of collective expertise in peptide synthesis, Motif Biotech has the technical capability to produce over 95% of the peptide drugs on the market. This capability is supported by a comprehensive service portfolio, spanning from peptide drug design and screening to structural modification and process optimization. The company's CRO and CDMO service offerings are designed to deliver high-quality, efficient solutions at competitive prices.

Motif Biotech's integrated platform provides fully customizable services for peptide-based therapeutics, covering every stage from early discovery and preclinical studies to cGMP manufacturing for clinical trial materials and commercial supply. Utilizing advanced solid-phase, liquid-phase, and hybrid synthesis techniques, the company produces high-purity bioactive peptides tailored to specific client requirements.

Guided by the principle of "Partner Success, Employee Growth, Corporate Excellence," Motif Biotech is on track to expand its annual GMP production capacity to over 100 kilograms by 2025. To solidify its leadership in the industrial CRDMO sector, the company is actively developing next-generation platforms, including technologies for peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs), and other complex modalities. These strategic initiatives are strengthening Motif Biotech's position as a global leader in the peptide CRDMO field.